Clinical and Pathological Studies in the Oldest Old

描述（由申请人提供）：项目摘要启动于2003年，90+研究的目标是在90岁及以上人群中进行前瞻性临床，病理和遗传研究。凭借90+研究中丰富的认知测试，实验室研究，身体表现测量，遗传和其他数据，以及自1981年以来作为休闲世界队列研究的一部分收集的关于这些人的调查信息，我们将估计发病率并评估痴呆症（目标1），功能残疾和虚弱（目标2）的风险和保护因素，以及老年人的认知和功能下降（目标3）。我们的研究强调了潜在的可改变因素（氧饱和度，贫血和身体表现）作为该年龄组痴呆和残疾的危险因素，并可能为未来最年长老年人的干预研究提供基础。基于我们的初步研究，我们假设动脉血氧饱和度差是认知能力下降和痴呆的危险因素，而贫血和身体表现指标（如步行速度和握力）是痴呆和非痴呆个体发生残疾、虚弱和功能下降的危险因素。在这个年龄段的所有痴呆症受试者中，有一半没有明显的经典AD或其他病理来解释认知丧失。在这项应用中，新的合作加强了我们的临床病理学研究，调查最古老的老年人认知的生物学相关性（目的4）。来自我们充分表征的受试者的脑组织将由加州大学欧文分校、宾夕法尼亚大学和约翰霍普金斯医学院的研究者进行研究，因为我们测试了我们的假设，即可溶性而不是不溶性的A2、tau和1突触核蛋白寡聚体种类可能是90岁以上奥尔兹人认知丧失的原因（Aim 4b），与神经元完整性和回路相关的衰老可能通过其他年龄相关机制导致认知丧失（目的4c）。最后，我们将开发我们的临床数据和生物样本（脑组织和DNA），作为与世界各地科学家积极共享的资源。

DESCRIPTION (provided by applicant): Project Summary Initiated in 2003, the goal of The 90+Study is to perform prospective clinical, pathological, and genetic investigations in a population based sample of people aged 90 years and older. With a wealth of cognitive tests, laboratory studies, physical performance measures, genetic and other data in The 90+ Study, plus survey information collected on these individuals since 1981 as part of the Leisure World Cohort Study, we will estimate incidence rates and evaluate risk and protective factors for dementia (Aim 1), functional disability and frailty (Aim 2), as well as cognitive and functional decline in the oldest old (Aim 3). Our studies emphasize potentially modifiable factors (oxygen saturation, anemia, and physical performance) as risk factors for dementia and disability in this age group, and could potentially provide the basis for future intervention studies in the oldest old. Based on our preliminary studies, we hypothesize that poor arterial oxygen saturation is a risk factor for cognitive decline and dementia, while anemia and physical performance measures (such as walk speed and handgrip) are risk factors for the development of disability, frailty, and functional decline in demented and non demented individuals. Half of all demented subjects in this age range do not have significant classical AD or other pathologies to explain cognitive loss. In this application, new collaborations enhance our clinical pathological studies investigating the biological correlates of cognition in the oldest old (Aim 4). Brain tissues from our well characterized subjects will be studied by investigators at the University of California, Irvine, University of Pennsylvania, and Johns Hopkins School of Medicine as we test our hypotheses that soluble, rather than insoluble, oligomeric species of A2, tau and 1 synuclein may be responsible for cognitive loss in 90+ year olds (Aim 4b) and that non AD pathologies, relevant to neuronal integrity and circuits, may contribute to cognitive loss through other age related mechanisms (Aim 4c). Finally, we will develop our clinical data and biological samples (brain tissues and DNA) as a resource to be actively shared with scientists worldwide.